Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Phaxiam Therapeutics SA News

    2,85 € +0,35% +0,01 €
    17.04.24 21:50:00 Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3EJH8
    ISIN: FR001400K4B1
    US-Symbol: ERYFF
    Typ: Aktie

    Phaxiam Therapeutics SA News

    15.04.24 - GlobeNewswire
    PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
    The study plans for the enrolment of 12 patients in 5 French clinical centers First study results expected in Q3 2024 This study will enable an evaluation of the intravenous ...
    05.04.24 - GlobeNewswire
    PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
    11.03.24 - GlobeNewswire
    PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
    Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative ...
    20.02.24 - GlobeNewswire
    PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
    PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
    14.11.23 - GlobeNewswire
    PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
    Conference call and webcast (English) on Wednesday, November 15, 2023
    24.10.23 - GlobeNewswire
    PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
    23.10.23 - GlobeNewswire
    TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation
    Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing ...
    19.09.23 - GlobeNewswire
    PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
    PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae , a new resistant and aggressive bacterial target
    18.09.23 - GlobeNewswire
    PHAXIAM Therapeutics announces the completion of its reverse share split
    PRESS RELEASE
    05.09.23 - GlobeNewswire
    PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
    P HAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
    08.08.23 - GlobeNewswire
    Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2023
    Monthly information related to total number of voting rights and shares composing the share capital _ Ju ly 31 , 202 3 . Article 223-16 of general regulation of French Autorité des ...
    27.07.23 - GlobeNewswire
    PHAXIAM Therapeutics announces a reverse share split of its shares
    PRESS RELEASE
    28.06.23 - GlobeNewswire
    Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
    P haxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
    26.06.23 - GlobeNewswire
    ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
    ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
    23.06.23 - GlobeNewswire
    ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023
    ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 2 3 , 202 3 All resolutions voted ...
    20.06.23 - GlobeNewswire
    ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit
    ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit
    14.06.23 - GlobeNewswire
    ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma
    ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma
    12.06.23 - GlobeNewswire
    ERYTECH Responds to Akkadian’s Disinformation
    ERYTECH Responds to Akkadian’s Disinformation
    05.06.23 - GlobeNewswire
    ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
    ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
    24.05.23 - GlobeNewswire
    ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
    ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 2 3 , 20 2 3

    Newssuche

    Videos

    newspaper
    16.04.24 -9,38%
    Technical Trading: Natural Gas Long Chance
    Erdgas Long Typ: Turbo Open End WKN: VM6KAH Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »